why choose us

First received: April 13, 2023

Clinical Trial: Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hematologic Malignancies

Study Type: INTERVENTIONAL


Official Title: IIT2022-03-Paquette-GeriBMT: A Phase I Study of De-Escalation of Post-Transplant Cyclophosphamide Dosing in Patients Aged >/= 70 Years Undergoing Conditioning With Fludarabine and Total Body I

Brief Summary: The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged >/= 70 years with hematologic malignancies.

Read more